|1.||Khan, Mohammad R: 1 article (05/2013)|
|2.||Shah, Syed Q: 1 article (05/2013)|
|3.||Owens, Robert C: 1 article (07/2005)|
|4.||Ambrose, Paul G: 1 article (07/2005)|
|5.||Oh, Young R: 1 article (07/2003)|
|6.||Crawley, Peter G: 1 article (07/2003)|
|7.||Probasco, James M: 1 article (07/2003)|
|8.||Carr-Lopez, Sian M: 1 article (07/2003)|
|9.||Kawamura, Yasuhito: 1 article (06/2002)|
|10.||Fukuda, Hitoshi: 1 article (06/2002)|
12/30/1991 - "Multiple clinical trials indicate that temafloxacin is also clinically effective, well tolerated, and safe for use in adult patients for the treatment of other lower respiratory tract, genitourinary tract, and skin and skin-structure infections."
12/30/1991 - "These results indicate that temafloxacin is useful in the treatment of mild to moderate skin and skin structure infections caused by staphylococci or streptococci."
06/01/1990 - "These data support further investigation of the efficacy of temafloxacin in treating serious infections caused by methicillin-resistant S. "
11/01/1993 - "These and other studies demonstrated that temafloxacin showed potential as an agent that could have been further developed for use in the treatment of anaerobic infections. "
02/01/1993 - "This study suggests that temafloxacin has potential for the treatment of anaerobic or mixed aerobic-anaerobic infections in man."
|2.||Respiratory Tract Infections (Respiratory Tract Infection)
12/01/1991 - "Temafloxacin has improved activity against pneumococci and its high oral bioavailability and excellent penetration into respiratory tissues now combine to provide a suitable profile for the management of a wider range of respiratory infections. "
07/01/1992 - "This study indicates that temafloxacin would be suitable for the empirical treatment of lower respiratory tract infections, including high-risk groups such as the elderly and heavy smokers."
12/30/1991 - "Early clinical trials confirm the clinical efficacy and safety of temafloxacin in the treatment of many common respiratory tract infections. "
12/30/1991 - "For strains of Mycoplasma pneumoniae and Chlamydia pneumoniae, temafloxacin was generally inhibitory at concentrations of 0.5-2 micrograms/mL. This microbiologic activity, combined with its pharmacokinetic profile, should make temafloxacin a useful antimicrobial agent for treating community-acquired respiratory tract infections."
12/01/1991 - "A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections."
|3.||Bacterial Infections (Bacterial Infection)
12/30/1991 - "Temafloxacin appears to be safe and effective for the management of bacterial infections of the skin and skin structure."
12/30/1991 - "Data were pooled from six clinical trials designed to evaluate the efficacy and safety of temafloxacin in bacterial infections of the lower respiratory tract. "
12/30/1991 - "A randomized, double-blind, multicenter study was conducted in 492 patients to compare the safety and efficacy of temafloxacin 600 mg with ciprofloxacin 750 mg for the treatment of bacterial infections of the skin or skin structure. "
12/01/1991 - "The safety and efficacy of a seven to 14 day course of temafloxacin 600 mg once daily were compared to ciprofloxacin 500 mg bd in adult patients with bacterial infections of the lower respiratory tract in a multicentre, double-blind, randomized clinical trial. "
12/01/1991 - "The preliminary results from this study suggest that once daily temafloxacin gives high rates of clinical and bacteriological success, similar to twice daily ciprofloxacin, in the management of bacterial infections in the lower respiratory tract."
05/01/1994 - "The clinical efficacy of temafloxacin (TMFX) was evaluated in the patients with acute prostatitis (AP: 31 cases) and chronic prostatitis (CP: 75 cases), and the criteria for clinical evaluation on bacterial prostatitis by the Japanese UTI Committee were re-examined. "
05/01/1994 - "[Re-examination of the criteria for clinical evaluation on bacterial prostatitis--analysis of the data of the clinical study of temafloxacin]."
12/30/1991 - "In an open multicenter study [corrected], 112 male patients (mean age 47.1 years) with documented symptomatic chronic bacterial prostatitis were treated with oral temafloxacin 400 mg b.i.d. "
12/30/1991 - "Treatment of chronic bacterial prostatitis with temafloxacin."
12/01/1991 - "Temafloxacin 400 mg bd, for four weeks was very effective and well tolerated by the majority of patients with documented bacterial prostatitis."
|5.||Urinary Tract Infections (Urinary Tract Infection)
12/30/1991 - "The safety and efficacy of temafloxacin were evaluated in a multicenter, double-blind study of patients with complicated urinary tract infections. "
12/30/1991 - "The clinical efficacy and safety of temafloxacin were assessed in adult females with acute, uncomplicated urinary tract infection in a series of three randomized, double-blind trials. "
12/30/1991 - "These results demonstrate the clinical efficacy and safety of temafloxacin, given once daily, in a large number of females with acute, uncomplicated urinary tract infection."
12/30/1991 - "Temafloxacin is a new fluoroquinolone that achieves a high urine concentration and has potent, broad-spectrum antimicrobial activity against most pathogens associated with urinary tract infections. "
12/30/1991 - "Treatment of uncomplicated urinary tract infections with temafloxacin."
|5.||Enoxacin (AT 2266)
|6.||sparfloxacin (AT 4140)
|4.||Renal Dialysis (Hemodialysis)